CHAM
REGN icon

Clear Harbor Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Clear Harbor Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400
Closed -$351K – 398
2023
Q4 		$351K Buy
+400
New +$329K 0.03% 264

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Clear Harbor Asset Management's REGN Position: Q1 2026 in Review

Clear Harbor Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 2.9% in Q1 2026, buying an estimated $238K and bringing the position to 10,875 shares worth $8.4M. The position accounts for 0.58% of the portfolio, ranked #39.

Clear Harbor Asset Management first reported a position in REGN in Q1 2021 and has held it in 21 quarters since. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Clear Harbor Asset Management held 10,875 shares of Regeneron Pharmaceuticals worth $8.4M as of Q1 2026.
  • Clear Harbor Asset Management bought 311 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $238K.
  • Regeneron Pharmaceuticals made up 0.58% of Clear Harbor Asset Management's portfolio in Q1 2026, its #39 holding.
  • Clear Harbor Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Clear Harbor Asset Management's 13F filing for Q1 2026, filed 5 May 2026.